Tag: China CDE
Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient...
Ascentage Pharma, a global biopharmaceutical company, has received approval from the Center for Drug Evaluation (CDE) of China’s National Medical Product Administration (NMPA) for...